{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:28:54Z","timestamp":1740166134823,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s13760-021-01769-0","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T09:04:20Z","timestamp":1629363860000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis"],"prefix":"10.1007","volume":"123","author":[{"given":"Xin","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaru","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyi","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-4898","authenticated-orcid":false,"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF01796261","volume":"44","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT (1995) Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44:317\u2013322","journal-title":"Inflamm Res"},{"issue":"6","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ard.2005.045641","volume":"65","author":"M Cutolo","year":"2006","unstructured":"Cutolo M, Capellino S, Montagna P, Sulli A, Seriolo B, Villaggio B (2006) Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. Ann Rheum Dis 65(6):728\u2013735","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1769_CR3","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/1756-185X.13599","volume":"22","author":"Q Dai","year":"2019","unstructured":"Dai Q, Xu L, Yu X (2019) Efficacy and safety of leflunomide in psoriatic arthritis treatment: a single-arm meta-analysis. Int J Rheum Dis 22(8):1498\u20131505","journal-title":"Int J Rheum Dis"},{"key":"1769_CR4","first-page":"107","volume":"2","author":"E Lubrano","year":"2012","unstructured":"Lubrano E, Scarpa R (2012) Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2:107\u2013112","journal-title":"Reumatismo"},{"issue":"4","key":"1769_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0192-0561(95)00009-Q","volume":"17","author":"B Vidic-Dankovic","year":"1995","unstructured":"Vidic-Dankovic B, Kosec D, Damjanovic M, Apostolski S, Isakovic K, Bartlett RR (1995) Leflunomide prevents the development of experimentally induced myasthenis gravis. Int J Immunopharmacol 17(4):273\u2013281","journal-title":"Int J Immunopharmacol"},{"issue":"1","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00415-015-7944-8","volume":"263","author":"P Chen","year":"2016","unstructured":"Chen P, Feng H, Deng J, Luo Y, Qiu L, Ou C, Liu W (2016) Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. J Neurol 263(1):83\u201388","journal-title":"J Neurol"},{"issue":"18","key":"1769_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB (2010) The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74(18):1434\u20131440","journal-title":"Neurology"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","volume":"32","author":"N Alcorn","year":"2009","unstructured":"Alcorn N, Saunders S, Madhok R (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32:1123\u20131134","journal-title":"Drug Saf"},{"key":"1769_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/14740338.2013.798299","volume":"12","author":"HI Keen","year":"2013","unstructured":"Keen HI, Conaghan PG, Tett SE (2013) Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf 12:581\u2013588","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1769_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ncl.2020.09.007","volume":"39","author":"C Bodkin","year":"2021","unstructured":"Bodkin C, Pascuzzi RM (2021) Update in the management of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Neurol Clin 39(1):133\u2013146","journal-title":"Neurol Clin"},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","volume":"369","author":"L Gotterer","year":"2016","unstructured":"Gotterer L, Li Y (2016) Maintenance immunosuppression in myasthenia gravis. J Neurol Sci 369:294\u2013302","journal-title":"J Neurol Sci"},{"issue":"3","key":"1769_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","volume":"175","author":"JP Sieb","year":"2014","unstructured":"Sieb JP (2014) Myasthenia gravis: an update for the clinician. Clin Exp Immunol 175(3):408\u2013418","journal-title":"Clin Exp Immunol"},{"key":"1769_CR13","first-page":"410","volume":"15","author":"J Morren","year":"2020","unstructured":"Morren J, Li Y (2020) Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci 15:410","journal-title":"J Neurol Sci"},{"issue":"14","key":"1769_CR14","first-page":"960","volume":"85","author":"Y Yang","year":"2005","unstructured":"Yang Y, Zhu X, Liang L, Zhan Z, Ye Y (2005) Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Nat Med J China 85(14):960\u2013962","journal-title":"Nat Med J China"},{"issue":"3","key":"1769_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International Consensus Guidance for Management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"2","key":"1769_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56(2):185\u2013196","journal-title":"Muscle Nerve"},{"issue":"3","key":"1769_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mus.26876","volume":"62","author":"SK Sahai","year":"2020","unstructured":"Sahai SK, Maghzi AH, Lewis RA (2020) Rituximab in late-onset myasthenia gravis is safe and effective. Muscle Nerve 62(3):377\u2013380","journal-title":"Muscle Nerve"},{"issue":"33","key":"1769_CR18","first-page":"2323","volume":"92","author":"H Feng","year":"2012","unstructured":"Feng H, Liu W, Huang X, Qiu L, Li Y, Wang H, Luo C (2012) Efficacy and safety of low -dose cyclophosphamide plus corticosteroids for type I\/II myasthenia gravis. Nat Med J China 92(33):2323\u20132326","journal-title":"Nat Med J China"},{"key":"1769_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","volume":"63","author":"L Wang","year":"2019","unstructured":"Wang L, Xi J, Zhang S, Wu H, Zhou L, Lu J, Zhang T, Zhao C (2019) Effectiveness and safety of tacrolimus therapy for myasthenia gravis: a single arm meta-analysis. J Clin Neurosci 63:160\u2013167","journal-title":"J Clin Neurosci"},{"issue":"45","key":"1769_CR20","first-page":"3102","volume":"91","author":"H Feng","year":"2011","unstructured":"Feng H, Liu W, Qiu L, Huang X, Huang R (2011) Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients. Nat Med J China 91(45):3102\u20133109","journal-title":"Nat Med J China"},{"issue":"7","key":"1769_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","volume":"8","author":"I Koneczny","year":"2019","unstructured":"Koneczny I, Herbst R (2019) Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells 8(7):671","journal-title":"Cells"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-021-01769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-021-01769-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-021-01769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T15:25:07Z","timestamp":1699370707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-021-01769-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s13760-021-01769-0","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the appropriate ethics committees in the first affiliated hospital of Sun Yat-sen University. All participants gave informed consent prior to enrollment in the study. All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The named authors consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The named authors consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}